Lincoln Pharmaceuticals Ltd
LINCOLNLincoln Pharmaceuticals Ltd
LINCOLN
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.63 | 2.25 | 0.27% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 407.51 | 362.99 | 366.07 | 371.78 | 397.53 | 429.85 | 482.12 | 532.78 | 614.97 | 629.35 | ||||||||||
Raw Materials | 281.90 | 224.23 | 195.49 | 164.92 | 191.33 | 193.75 | 232.15 | 245.64 | 284.04 | 490.29 | ||||||||||
| Power & Fuel Cost | 5.68 | 5.92 | 6.82 | 7.21 | 8.18 | 7.10 | 8.33 | 10.25 | 11.47 | |||||||||||
| Employee Cost | 28.83 | 37.59 | 51.15 | 51.90 | 58.65 | 63.26 | 79.72 | 93.16 | 102.90 | |||||||||||
| Selling & Administrative Expenses | 30.51 | 36.71 | 40.96 | 44.28 | 50.88 | 51.00 | 50.90 | 54.46 | 61.00 | |||||||||||
| Operating & Other expenses | 12.70 | 9.03 | 13.87 | 30.60 | 11.92 | 21.90 | 5.54 | 17.60 | 21.23 | |||||||||||
EBITDA | 47.89 | 49.51 | 57.78 | 72.87 | 76.57 | 92.84 | 105.48 | 111.67 | 134.33 | 139.06 | ||||||||||
| Depreciation/Amortization | 4.87 | 5.51 | 6.11 | 6.68 | 7.33 | 7.56 | 8.09 | 9.17 | 10.62 | 11.30 | ||||||||||
| PBIT | 43.02 | 44.00 | 51.67 | 66.19 | 69.24 | 85.28 | 97.39 | 102.50 | 123.71 | 127.76 | ||||||||||
| Interest & Other Items | 9.96 | 6.66 | 5.41 | 4.00 | 2.02 | 1.56 | 1.45 | 2.03 | 1.46 | 1.48 | ||||||||||
| PBT | 33.06 | 37.34 | 46.26 | 62.19 | 67.22 | 83.72 | 95.94 | 100.47 | 122.25 | 126.28 | ||||||||||
| Taxes & Other Items | 9.38 | 9.21 | 11.62 | 13.48 | 15.80 | 21.47 | 26.58 | 27.58 | 28.93 | 28.30 | ||||||||||
| Net Income | 23.68 | 28.13 | 34.64 | 48.71 | 51.42 | 62.25 | 69.36 | 72.89 | 93.32 | 97.98 | ||||||||||
| EPS | 14.52 | 15.49 | 17.32 | 24.35 | 25.71 | 31.10 | 34.63 | 36.39 | 46.59 | 48.92 | ||||||||||
| DPS | 1.00 | 1.20 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.80 | 1.50 | ||||||||||
| Payout ratio | 0.07 | 0.08 | 0.09 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | 14.31 | 2.25 | 0.27% |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare LINCOLN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.24%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Lincoln Pharmaceuticals Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 95/102 (-3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
LINCOLN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.70 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 13, 2024
Dividend/Share
₹1.80
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateMar 5, 2020
Dividend/Share
₹1.50
Ex DateEx Date
Mar 5, 2020
Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Lincoln Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Lincoln Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Net profit of Lincoln Pharmaceuticals rose 24.51% to Rs 23.67 crore in the quarter ended June 2024 as against Rs 19.01 crore during the previous quarter ended June 2023. Sales rose 8.60% to Rs 147.28 crore in the quarter ended June 2024 as against Rs 135.62 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales147.28135.62 9 OPM %15.4315.28 - PBDT32.7027.99 17 PBT29.4825.45 16 NP23.6719.01 25 Powered by Capital Market - Live
Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
Sensex, Nifty settle higher in volatile trade; AEL & Bajaj Auto rises 3% each; Lincoln Pharma falls 11%
Lincoln Pharmaceuticals Reports Strong Profit Growth and Dividend Recommendation
Lincoln Pharma Standalone December 2022 Net Sales at Rs 133.77 crore, up 11.58% Y-o-Y
Lincoln Pharma tumbles after weak Q4 performance
Hot Stocks | Double-digit Returns From Lincoln Pharma, Globus Spirits, Dalmia Bharat Possible In Short Term. Here’s Why
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.59%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.17% to 0.16%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 13.89%, vs industry avg of 15.28%